FDA Approves Donidalorsen as First RNA-Targeted Prophylactic Treatment for Hereditary Angioedema
Published: August 21st 2025 | Updated: August 21st 2025The FDA approves donidalorsen, the first RNA-targeted therapy for hereditary angioedema, offering significant attack reduction and convenient administration.